Bortezomib Treatment Modulates Autophagy in Multiple Myeloma

Although the introduction of bortezomib as a therapeutic strategy has improved the overall survival of multiple myeloma (MM) patients, 15–20% of high-risk patients do not respond to bortezomib over time or become resistant to treatment. Therefore, the development of new therapeutic strategies, such...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Lernia, Giuseppe, Leone, Patrizia, Solimando, Antonio Giovanni, Buonavoglia, Alessio, Saltarella, Ilaria, Ria, Roberto, Ditonno, Paolo, Silvestris, Nicola, Crudele, Lucilla, Vacca, Angelo, Racanelli, Vito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073518/
https://www.ncbi.nlm.nih.gov/pubmed/32085480
http://dx.doi.org/10.3390/jcm9020552

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073518/
https://www.ncbi.nlm.nih.gov/pubmed/32085480
http://dx.doi.org/10.3390/jcm9020552

Ejemplares similares